login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MANNKIND CORP (MNKD) Stock News
USA
-
Nasdaq
- NASDAQ:MNKD -
US56400P7069
-
Common Stock
5.35
USD
-0.03 (-0.56%)
Last: 11/28/2025, 7:48:44 PM
5.4
USD
+0.05 (+0.93%)
Pre-Market:
12/1/2025, 8:12:16 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MNKD Latest News, Press Relases and Analysis
All
Press Releases
26 minutes ago - By: MannKind
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
26 minutes ago - By: MannKind
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
20 days ago - By: MannKind
MannKind to Present at the Jefferies Global Healthcare Conference
20 days ago - By: MannKind
MannKind to Present at the Jefferies Global Healthcare Conference
25 days ago - By: Stocktwits
MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century
26 days ago - By: Stocktwits
- Mentions:
URTY
PBE
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters
a month ago - By: Benzinga
- Mentions:
TECH
INSE
GEF
SKYT
...
Earnings Scheduled For November 5, 2025
21 days ago - By: MannKind
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
25 days ago - By: MannKind
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
26 days ago - By: Zacks Investment Research
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
3 months ago - By: Stocktwits
- Mentions:
UTHR
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
3 months ago - By: Stocktwits
- Mentions:
UTHR
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together
26 days ago - By: Zacks Investment Research
- Mentions:
OVID
MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
a month ago - By: MannKind
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: MannKind
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: Zacks Investment Research
- Mentions:
PTGX
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?
a month ago - By: MannKind
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
3 months ago - By: Zacks Investment Research
- Mentions:
CVGI
INBK
New Strong Sell Stocks for August 27th
a month ago - By: MannKind
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
2 months ago - By: MannKind
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
2 months ago - By: MannKind
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
2 months ago - By: MannKind
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
2 months ago - By: MannKind
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
2 months ago - By: MannKind
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
2 months ago - By: MannKind
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
3 months ago - By: Zacks Investment Research
- Mentions:
DNLI
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
3 months ago - By: Benzinga
- Mentions:
INSM
CNC
MOH
UNH
...
10 Health Care Stocks Whale Activity In Today's Session
3 months ago - By: Yahoo Finance
MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza
3 months ago - By: Brodsky & Smith LLC
- Mentions:
SCPH
VTLE
IMXI
HBI
...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)
3 months ago - By: MannKind
MannKind to Present at Upcoming Investor Conferences
3 months ago - By: MannKind
MannKind to Present at Upcoming Investor Conferences
3 months ago - By: MannKind
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
3 months ago - By: MannKind
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
Please enable JavaScript to continue using this application.